Research Paper Volume 15, Issue 18 pp 9809—9821
The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1
- 1 Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, P.R. China
Received: May 16, 2023 Accepted: August 29, 2023 Published: September 21, 2023
https://doi.org/10.18632/aging.205051How to Cite
Copyright: © 2023 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Lines of evidence have demonstrated that the oncogenic miRNAs are pivotal to the progression of breast cancer. In this study, we investigated the biological traits of microRNA-429 (miR-429) in triple-negative breast cancer (TNBC) and the underlying molecular mechanism. We found that miR-429 was notably overexpressed in TNBC, and promoted TNBC cell proliferation, migration, and invasion by degrading the tumor suppressor DLC1. In conclusion, our findings reveal the mechanism of tumorigenic miR-429 in TNBC, which paves the way for target therapies translation in clinical settings.
Abbreviations
DEmRNAs: differentially expressed mRNAs; DLC1: Hepatocellular carcinoma deletion gene 1; ER: estrogen receptor; EMT: epithelial-to-mesenchymal transition; FDR: false discovery rate; FFPE: formalin-fixed paraffin-embedded; HER-2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; HE: Hematoxylin and eosin; IRB: Institutional Review Board; miR-429: microRNA-429; MOD: Mean optical density; OS: overall survival; PBS: phosphate-buffered saline; PTEN: Phosphatase and tensin homolog; PR: progesterone receptor; qRT-PCR: quantitative real-time polymerase chain reaction; SD: standard deviation; TCGA: The Cancer Genome Atlas; TNBC: triple-negative breast cancer.